Control Bionics Ltd. is a medical device company specializing in the development, commercialization, and sale of advanced assistive communication technology systems. Founded in 2005 and headquartered in Cremorne, Australia, the company is dedicated to enhancing communication and control capabilities for individuals with speech and movement impairments. Its product suite includes the NeuroNode Trilogy, NeuroNode Duo, and Eye-gaze Duo, which utilize bioelectric signal and eye-tracking technology to allow users to generate speech, interact with computers, and manage other electronic devices. Additional offerings like Cosmos Connect and Uno Touch further expand access to digital communications for those with severe physical disabilities. Serving markets in Australia, North America, and globally, Control Bionics Ltd. plays a vital role within the healthcare sector—particularly in the area of augmentative and alternative communication (AAC) technology. Its solutions are integral for users seeking greater independence and improved quality of life, positioning the company as an important innovator in medical and assistive technologies.